Pipeline

Pipeline Overview

Click to learn about the trilaciclib mechanism of action

G1 is advancing a pipeline of potential best-in-class and first-in-class drug candidates in multiple oncology indications. Our drug candidates are designed to be administered in combination with many conventional and emerging cancer therapeutics.

We have exclusive worldwide development and commercialization rights to trilaciclib, lerociclib and G1T48, with more than 115 U.S. and international patents and pending patent applications covering our development programs. We are also exploring a number of preclinical compounds that have been discovered and synthesized by our in-house discovery team.

trilaciclib

IV CDK4/6i

1st-Line Small Cell Lung Cancer (+ etop/carbo)

   

1st-Line Small Cell Lung Cancer (+ etop/carbo/Tecentriq®)

   

2nd-/3rd-Line Small Cell Lung Cancer (+ topotecan)

   

Metastatic Triple-Negative Breast Cancer (+ gem/carbo)

   

lerociclib

oral CDK4/6i

Estrogen Receptor-Positive, HER2-negative Breast Cancer (+ Faslodex®)

   

Epidermal Growth Factor Receptor mutant Non-Small Cell Lung Cancer (+ Tagrisso®)

   

G1T48

oral SERD

Estrogen Receptor-Positive, HER2-negative Breast Cancer (monotherapy)